ABCSG 57 / ALPHABET Overview
A randomized phase III trial of trastuzumab + alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ advanced breast cancer
| Study Start: | AT: 09/2022 Global: 10/2021; FPI 10/2021 |
| Coordinating Investigator: | AT: Marija Balic, Graz |
| Sample Size: | AT: 30 Global: 252 |
| Study Design: (Click to enlarge) |
 |
Share on